Our retrospective case-control study suggests that VIDPP-4i (i.e., vitamin D3 plus sitagliptin) exposure in addition to insulin therapy may substantially prolong the duration of the clinical remission phase in a population of children, adolescents, and young adults with new-onset T1D. The gene discussed is INS; the disease is type 1 diabetes mellitus.